Therapeutic Contract in Adolescents Using Hybrid Closed Loop System

not require

structural reliability of rc elements with electric arc furnace slag as recycled aggregates

n/

Placental determinants of fetal growth: identification of key factors in the insulin-like growth factor and cytokine systems using artificial neural networks

<p>Abstract</p> <p>Background</p> <p>Changes and relationships of components of the cytokine and IGF systems have been shown in placenta and cord serum of fetal growth restricted (FGR) compared with normal newborns (AGA). This study aimed to analyse a data set of clinical and biochemical data in FGR and AGA newborns to assess if a mathematical model existed and was capable of identifying these two different conditions in order to identify the variables which had a mathematically consistent biological relevance to fetal growth.</p> <p>Methods</p> <p>Whole villous tissue was collected at birth from FGR (N = 20) and AGA neonates (N = 28). Total RNA was extracted, reverse transcribed and then real-time quantitative (TaqMan) RT-PCR was performed to quantify cDNA for IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IL-6. The corresponding proteins with TNF-α in addition were assayed in placental lysates using specific kits. The data were analysed using Artificial Neural Networks (supervised networks), and principal component analysis and connectivity map.</p> <p>Results</p> <p>The IGF system and IL-6 allowed to predict FGR in approximately 92% of the cases and AGA in 85% of the cases with a low number of errors. IGF-II, IGFBP-2, and IL-6 content in the placental lysates were the most important factors connected with FGR. The condition of being FGR was connected mainly with the IGF-II placental content, and the latter with IL-6 and IGFBP-2 concentrations in placental lysates.</p> <p>Conclusion</p> <p>These results suggest that further research in humans should focus on these biochemical data. Furthermore, this study offered a critical revision of previous studies. The understanding of this system biology is relevant to the development of future therapeutical interventions possibly aiming at reducing IL-6 and IGFBP-2 concentrations preserving IGF bioactivity in both placenta and fetus.</p

First description of LADY with DKA and in a male adolescent

3noopenopenTornese G, Faleschini E,Barbi E.Tornese, G; Faleschini, E; Barbi, E

Safety and effectiveness of advanced hybrid closed loop system in children younger than 7 years

Introduction: The advanced hybrid closed loop (a-HCL) system Medtronic Minimed 780G is licensed for use in children ≥7 years and with a minimum insulin daily dose ≥ of 8 units. Objectives: To study the safety and the effectiveness of the a-HCL system Medtronic Minimed 780G in children younger than 7 years. Methods: Retrospective study in children with type 1 diabetes mellitus (T1DM) who started using a-HCL before the age limit of 7 years when the clinician considered this treatment to be beneficial, and the family agreed on off-label use of the system. The “G2 clinico” platform was employed to access patients' clinical data. We extracted the latest data on glycemic control from reports generated with Care- LinkTM Personal Software with observation time frames of 2 weeks. Data are presented as median and interquartile ranges (IQRs). Wilcoxon signed-rank test was performed to check whether the differences between paired data were statistically significant. Results: This retrospective study included 10 individuals (5 females) with T1DM (median age at diagnosis 3.8 years [IQR 2.5;4.9]). The median duration of T1DM was 37 days (IQR 5; 418) at the beginning of insulin pump in manual mode and 164 days (IQR 32–451; min 14 days) when starting treatment with a-HCL in auto mode, at a median age of 4.7 years (IQR 2.9; 5.5, min 2.1 years) and with a median insulin daily requirement of 9.4 U (IQR 8.1;11.6, min 5.6). The median age at the last data download was 5.1 years (IQR 3.3–6.6), with a median duration of a-HCL treatment of 179 days (IQR 72;385). No ketoacidosis or severe hypoglycemia events were reported. Time above range (TAR) and mean glucose sensor significantly decreased since the beginning of a-HCL use and until the last download (p < 0.01), while time in range (TIR) significantly reduced (p < 0.01). Conclusions: The use of a-HCL system Minimed 780G is safe and effective also in children below the age of 7 years and with a total daily insulin dose below 8 U

Diagnosis of diabetes. What about cystic fibrosis?

No abstract availabl